Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study) by Tadaaki Yamada, Junji Uchino, Yusuke Chihara, Takayuki Shimamoto, Masahiro Iwasaku, Nobuyo Tamiya, Yoshiko Kaneko, Fumiaki Kiyomi, Koichi Takayama

“…Background: In the PACIFIC study, progression-free survival (PFS) and overall survival (OS) of patients with unresectable, locally advanced, stage III non-small cell lung cancer (NSCLC) were prolonged by durvalumab as maintenance therapy after radical concurrent chemoradiotherapy using platinum-based antitumor agents. …”
Get full text

Evaluation of the Prognostic Impact of SP263-Evaluated PD-L1 Expression in Patients with Stage III Non-Small Cell Lung Cancer (NSLC) Treated with Radio-Chemotherapy by Jan Nicolai Wagner, Julia Roeper, Lukas Heukamp, Markus Falk, Kay Willborn, Frank Griesinger

“…Background: The PACIFIC study showed that after radio-chemotherapy, patients with NSCLC derived a benefit in PFS and OS when treated with durvalumab. …”
Get full text

A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation‐positive non‐small cell lung cancer (stage III)... by Juwhan Choi, Jeong Eun Lee, Chang‐Min Choi, In‐Jae Oh, Kye Young Lee, Tae Won Jang, Seung Hyeun Lee, Eun Young Kim, Dong Won Park, Sun Hyo Park, Sung Yong Lee

“…Abstract Introduction The PACIFIC study demonstrated that durvalumab consolidation therapy significantly improved progression‐free survival (PFS) and overall survival (OS) in patients with unresectable stage III non‐small cell lung cancer (NSCLC) after concurrent chemoradiotherapy (CCRT). …”
Get full text

Hydrosedimentary monitoring of the Hydrothiem observatory, Eastern tropical coast of New Caledonia (SW Pacific) by Pierre Genthon, Caroline Tramier, Quentin Delvienne, Pascal Dumas, Nathalie Rouché, Kavya Wijesuriya, Jean-Jerôme Cassan, Angelline Goué

“…Study region: The eastern coast of New Caledonia (SW Pacific). Study focus: The HydroThiem hydrological observatory is devoted to the study of the impact of invasive ungulate species and bushfires on water resources, erosion and water quality in a catchment used for drinking water. …”
Get full text

The role of chemoradiotherapy and immunotherapy in stage III NSCLC by Zsuzsanna Orosz, Árpád Kovács

“…For unresectable stage III NSCLC, definitive concurrent chemoradiotherapy (CCRT) was historically recommended as a treatment with a 5-year survival rate ranging from 20% to 30%. The PACIFIC study conducted in 2017 compared the use of chemoradiotherapy and maintenance therapy with the anti-PD-L1 monoclonal antibody durvalumab to a placebo in patients with locally advanced NSCLC who had not experienced disease progression. …”
Get full text

Additional Value and Business Efficiency of Various Processing Bananas Product in The Border Area of Sebatik Island by Fairuz Indana, Irham Irham, Jangkung Handoyo Mulyo

Get full text

Predictability of the East Africa long rains through Congo zonal winds by Neil Ward, Dean P. Walker, Richard J. Keane, John H. Marsham, Adam A. Scaife, Cathryn E. Birch, Ben Maybee

“…Indeed, the clear signals found in the Atlantic (including Mediterranean) and Indo‐Pacific, studied here both in observations and a dynamical prediction system, motivate evaluation of these features across other prediction systems, and offer the prospect of improved physically‐informed long rains dynamical predictions.…”
Get full text

Durvalumab Treatment Patterns for Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Veterans Health Administration (VHA): A Nationwide, Real-World Study by Amanda M. Moore, Zohra Nooruddin, Kelly R. Reveles, Paromita Datta, Jennifer M. Whitehead, Kathleen Franklin, Munaf Alkadimi, Madison H. Williams, Ryan A. Williams, Sarah Smith, Renee Reichelderfer, Ion Cotarla, Lance Brannman, Andrew Frankart, Tiernan Mulrooney, Kristin Hsieh, Daniel J. Simmons, Xavier Jones, Christopher R. Frei

“…Conclusions: These real-world analyses corroborate PACIFIC study results in terms of the main reasons for treatment discontinuation in a VHA population with worse prognostic factors, including older age, predominantly male sex, and poorer performance score. …”
Get full text

Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non–Small Cell Lung Cancer: Emerging Mechanisms and Perspectives by Inoue H, Okamoto I

“…Durvalumab (MEDI4736) is a high-affinity human immunoglobulin G1 monoclonal antibody that blocks the binding of PD-L1 on tumor cells or antigen-presenting cells to PD-1 on T cells. The PACIFIC study recently evaluated consolidation immunotherapy with durvalumab versus placebo administered after concurrent chemoradiotherapy (CCRT) in patients with unresectable stage III NSCLC. …”
Get full text

A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI s... by Hisashi Tanaka, Shigeru Tanzawa, Toshihiro Misumi, Tomonori Makiguchi, Megumi Inaba, Takeshi Honda, Junya Nakamura, Koji Inoue, Takayuki Kishikawa, Masanao Nakashima, Keiichi Fujiwara, Tadashi Kohyama, Hiroo Ishida, Shoichi Kuyama, Naoki Miyazawa, Tomomi Nakamura, Hiroshi Miyawaki, Naohiro Oda, Nobuhisa Ishikawa, Ryotaro Morinaga, Kei Kusaka, Nobukazu Fujimoto, Yasushi Fukuda, Masayuki Yasugi, Takeshi Tsuda, Sunao Ushijima, Kazuhiko Shibata, Takuo Shibayama, Akihiro Bessho, Kyoichi Kaira, Kenshiro Shiraishi, Noriyuki Matsutani, Nobuhiko Seki

“…Background: The standard of care for unresectable, locally advanced non-small-cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT) followed by durvalumab, based on the PACIFIC study. Although multiple Japanese phase II studies have shown high efficacy and tolerability of CRT with cisplatin plus S-1 (SP), no prospective study using durvalumab after SP-based CRT has been reported. …”
Get full text